ASNRT — Arab Society of Nephrology and Renal Transplantation

النسخة العربية من هذه الصفحة

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

Post-trial follow-up of EMPA-KIDNEY showed that empagliflozin's cardiorenal benefits in chronic kidney disease persisted for up to about 12 months after the drug was discontinued.

Category

Research

Source

N Engl J Med

Read the original article

More from ASNRT News

Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.

All news · ASNRT home